Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

Document › Details

Themis Bioscience N.V.. (11/8/18). "Press Release: Themis Bioscience Postpones Its Listing on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna.

	Region	Amsterdam
	Country	Netherlands
	Organisation	Themis Bioscience N.V.
	Group	Themis Bioscience (Group)
	Organisation 2	Euronext Amsterdam N.V.
	Group	Euronext (Group)
	Product	Measles Vector (MV) technology platform
	Product 2	investment banking
	Index term	Themis Bioscience–SEVERAL: investment, 201810– IPO €35m to €55.3m on Euronext Amsterdam POSTPONED 11/18
	Person	Tauber, Erich (Themis Bioscience GmbH 201505 CEO)
	Person 2	May, Stephanie (Trophic Communications 201801 before MacDougall European Office)

Original document
accessed by [iito] on 2018-11-11

Record changed: 2018-11-12

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Themis Bioscience (Group)

[1] Themis Bioscience GmbH. (10/29/19). "Press Release: Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine". Vienna & Oslo....
[2] Themis Bioscience GmbH. (9/18/19). "Press Release: Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline". Vienna....
[3] Themis Bioscience GmbH. (8/22/19). "Press Release: Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates". Vienna....
[4] Themis Bioscience GmbH. (6/4/19). "Press Release: CEPI Awards up to US$21 Million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development". Vienna & Oslo....
[5] Themis Bioscience GmbH. (2/25/19). "Press Release: Themis Bioscience Receives FDA Fast Track Designation for Chikungunya Vaccine Candidate". Vienna....
[6] Themis Bioscience GmbH. (11/5/18). "Press Release: Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet". Vienna....
[7] Themis Bioscience N.V.. (10/29/18). "Press Release: Themis Bioscience Launches its Initial Public Offering on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
[8] Themis Bioscience GmbH. (6/11/18). "Press Release: Themis Receives EMA PRIME Designation for Chikungunya Vaccine". Vienna....
[9] Themis Bioscience GmbH. (1/4/18). "Press Release: Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline". Vienna....
[10] Themis Bioscience GmbH. (6/6/17). "Press Release: NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine". Vienna....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top